Periodic fever syndromes.
Lachmann HJ.
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):596-609. doi: 10.1016/j.berh.2017.12.001. Epub 2018 Jan 11.
Neutrophilic urticarial dermatosis: A review.
Gusdorf L, Lipsker D.
Ann Dermatol Venereol. 2018 Dec;145(12):735-740. doi: 10.1016/j.annder.2018.06.010. Epub 2018 Sep 14.
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA.
Nat Med. 2015 Mar;21(3):248-55. doi: 10.1038/nm.3806. Epub 2015 Feb 16.
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.
Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD.
Nat Med. 2015 Mar;21(3):263-9. doi: 10.1038/nm.3804. Epub 2015 Feb 16.
Systemic autoinflammatory diseases: Clinical state of the art.
Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V.
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101529. doi: 10.1016/j.berh.2020.101529. Epub 2020 Jun 13.
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.
Zhan X, Li Q, Xu G, Xiao X, Bai Z.
Front Immunol. 2023 Jan 18;13:1109938. doi: 10.3389/fimmu.2022.1109938. eCollection 2022.
KCNN4 links PIEZO-dependent mechanotransduction to NLRP3 inflammasome activation.
Ran L, Ye T, Erbs E, Ehl S, Spassky N, Sumara I, Zhang Z, Ricci R.
Sci Immunol. 2023 Dec 22;8(90):eadf4699. doi: 10.1126/sciimmunol.adf4699. Epub 2023 Dec 22.
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, Benseler S, Berard R, Broderick L, Dedeoglu F, Diebold M, Durrant KL, Ferguson P, Foell D, Hausmann J, Jones OY, Kastner DL, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman H, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E.
Ann Rheum Dis. 2022 Jul;81(7):907-921. doi: 10.1136/annrheumdis-2021-221801. Epub 2022 May 27.
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O.
Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392. eCollection 2022.
CAPS and NLRP3.
Booshehri LM, Hoffman HM.
J Clin Immunol. 2019 Apr;39(3):277-286. doi: 10.1007/s10875-019-00638-z. Epub 2019 May 10.
